A lthough many of the treatment recommendations have changed, the overall structure of the new guideline on Parkinson's disease in adults (NG71) 1 is similar to the 2006 version. Advice on communicating with patients and howand how not to -diagnose the disorder precede the sections on drug therapy that make up the bulk of the guideline. However, unlike in 2006, the 2017 guidance is primarily symptom-led rather than focusing on classes of drugs. Non-pharmacological interventions, therapies for advanced disease, and an expanded section on palliative care conclude the guideline. 
Communicating with patients and families
The advice in this section is unchanged from 2006. The underlying philosophy is to empower patients and their families so they can participate in treatment decisions and to do so in a way that provides "a balance between providing honest, realistic information about the condition and promoting a feeling of optimism." Communications must be tailored to the abilities of the patient and family to understand, inform them of their entitlement to care support, and set out a care plan and contact details for health professionals. The DVLA must be informed of a diagnosis of Parkinson's disease.
Diagnosis
Although the new guideline suggests that many statements have been updated, little advice about diagnosis has changed. The red flag signs are tremor, stiffness, slowness, balance problems and/or gait disorders, and a suspicion of Parkinson's disease warrants prompt referral to a specialist with suitable expertise before initiating treatment. 
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Pharmacological management
Recommendations on drug treatment are divided into three main sections: the management of motor symptoms, managing and monitoring impulse control disorders induced by dopaminergic therapy and the management of non-motor symptoms. A fourth section consists entirely of NICE's 'Do not do' advice on prescribing neuroprotection, which advises not to use vitamin E nor (unless within a clinical trial) co-enzyme Q10, dopamine agonists or monoamine oxidase B (MAO-B) inhibitors as neuroprotective therapy.
Management of motor symptoms
Before prescribing treatment for motor symptoms, clinicians should discuss with patients how their medication can be tailored to their needs. This should cover the person's particular symptoms, co-morbidities and risks from polypharmacy; their lifestyle circumstances, preferences, needs and goals; and the potential benefits and harms of the different drug classes. NICE includes a helpful table comparing the effects of the major drug classes on symptoms and their adverse effects (see Table 1 ).
The precautions against sudden changes in medication survive from the 2006 guidance. These state that sudden interruptions and drug holidays (which aim to reduce the risk of motor complications) should be avoided because they may provoke neuroleptic malignant syndrome or acute akinesia. Consequently, doses should be taken at the right time and no changes should be made without advice from a specialist.
The choice of first-line treatment in early Parkinson's disease depends on the impact of symptoms. For those whose motor symptoms affect their quality of life, the drug of choice is levodopa. Where they have no such impact, there is a choice between levodopa, dopamine agonists (but not ergot-derived agents such as cabergoline, pergolide or bromocriptine because of the risk of cardiac fibrosis) and MAO-B inhibitors. Patients, families and carers should be informed about the risks of treatment, including impulse control disorders and psychotic symptoms (and the higher risk with dopamine agonists) as well as excessive sleepiness and sudden onset of sleep with dopamine agonists.
When dyskinesia and/or motor fluctuations such as 'wearing off' develop despite optimal levodopa therapy, adjuvant medication should be considered (on specialist advice). The options are: a dopamine agonist, an MAO-B inhibitor or a catechol-O-methyltransferase (COMT) inhibitor. The pros and cons of these different classes are again summarised in Table 2 . The table includes the dopamine agonist amantadine only to point out that there is no evidence to support its use. It is recommended as an option only when other agents have failed. Again, non-ergot dopamine agonists are preferred -in this case to avoid the echocardiography necessary to monitor patients for adverse effects. However, an ergot-derived agent can be considered if one of the preferred options is ineffective. Anticholinergic agents should not be prescribed.
Managing impulse control disorders
Impulse control disorders can develop with any dopaminergic therapy, not only dopamine agonists, and at any stage in the progress of Parkinson's disease. Other than drug treatment, the risk factors are a history of impulsive behaviours, a history of alcohol consumption and smoking. This issue should be discussed with patient, family and carers when starting treatment with a dopamine agonist and at review appointments, especially if treatment is modified. These discussions should cover the increased risk of developing impulse control disorders and the possibility that the patient may conceal them; the behaviours that may develop (including compulsive gambling, hypersexuality, binge eating and obsessive shopping); and who to contact if they do occur. Patients should be aware that treatment will be reviewed and may be reduced or discontinued when impulse control disorders are problematic.
The onset of an impulse control disorder is an indication for specialist referral before modifying treatment. Patients, families and carers need to think about how the impulse control disorder is affecting their life, what their options are (reducing or stopping the drug) and the benefits and disadvantages of each choice. If the decision is to modify treatment, the dose of dopamine agonist should initially be reduced slowly, monitoring the impulse control disorder and being vigilant for symptoms of dopamine agonist withdrawal. If this option fails, the next step is specialist cognitive behavioural therapy (CBT) targeted at the disorder.
Managing non-motor symptoms
Parkinson's disease is much more than a disorder affecting motor function, and drug treatment of its many other symptoms can result in a high level of polypharmacy especially if the patient is being treated for other co-morbidities associated with ageing. Parkinson's disease l NEW FROM NICE ■ Sleep disturbance takes several forms. Daytime sleepiness or sudden-onset sleep should first be addressed by stopping driving and avoiding hazards at work. After specialist advice, it may be possible to modify treatment to reduce the risk but if there is no remedy in adjusting treatment or behaviour, the narcolepsy drug modafinil is an option for excessive daytime sleepiness. This treatment requires annual review by a specialist.
NICE recommends: "Take care to identify and manage restless leg syndrome and rapid eye movement sleep behaviour disorder" in individuals with sleep disturbance. The options for treatment of rapid eye movement sleep behaviour disorder are both medicines not licensed for this indication -clonazepam and melatonin -but they should be considered if no possible pharmacological causes can be found. Nocturnal akinesia should first be treated with levodopa or an oral dopamine agonist and, if the first is not effective, the other should be tried. If both fail, rotigotine may be considered.
Or thostatic hypotension may be caused or exacerbated by medication for co-morbidities and treatment should be reviewed for possible contributors among antihypertensive drugs (including diuretics), dopaminergic or anticholinergic agents, and antidepressants. If this is unhelpful, the sympathomimetic midodrine is the preferred option (though it has many contraindications and its use requires monitoring for hypertension). If that is unsuitable, the next choice is fludro cortisone but NICE notes that it poses a cardiac risk and is associated with the risk of drug interactions.
Strategies other than drug therapy are preferred for drooling of saliva, but if a drug is necessary, the first choice is the poorly-absorbed anticholinergic agent glycopyrronium bromide. This is an unlicensed indication but the risk of adverse cognitive effects with other anticholinergics means that they have limited potential. If they are necessary, topical application should be used if possible. The final pharmacological option is botulinum toxin A, which requires referral to a specialist service.
NICE refers to its 2009 guideline Depression in Adults with a Chronic Physical Health Problem (CG91)
2 for advice on the management of depression in people with Parkinson's disease. The possible development of delusions and hallucinations should be checked at every review and any identifiable underlying cause should be treated. There is no need to treat the delusions/hallucinations "if they are well tolerated by the person with Parkinson's disease and their family members and carers (as appropriate)" but, if advised by a specialist and the disease severity allows, the dose of anti parkinson medication can be reduced. When antipsychotic treatment is needed specifically for delusions/ hallucinations and the individual is not cognitively impaired, the first choice is quetiapine and the second choice clozapine. Both are used at lower doses than are required for other indications. Olanzapine is not a recommended option and other antipsychotics, notably the phenothiazines and butyrophenones, may worsen motor symptoms due to their anticholinergic activity.
Recommendations 
Non-pharmacological interventions
This section seems to be an endorsement of the role of the Parkinson's
Dopamine agonists MAO-B inhibitors COMT inhibitors Amantadine
Motor symptoms Improvement in motor symptoms
Improvement in motor symptoms
No evidence of improvement in motor symptoms 
Activities of daily living
Treatments for advanced Parkinson's disease
Optimising medical therapy is fundamental to the management of advanced Parkinson's disease. The last pharmacological step, in addition to standard medication, is apomorphine, administered by intermittent injection and/ or continuous subcutaneous infusion. When best medical therapy no longer controls symptoms, the final option is deep brain stimulation. The guideline does not give recommendations on levodopa-carbidopa intestinal gel, instead suggesting that NHS England reviews its current clinical commissioning policy for this preparation.
Palliative care
As hinted at the outset, coping with a diagnosis of Parkinson's disease can be difficult. Referral to the palliative care service can be offered at any time to give everyone the chance to talk about what palliative care entails, recognising that patients' needs may not be the same as those of their family or carers. There should be plenty of opportunities to talk about the prognosis -in ways, NICE recommends, that "promote people's priorities, shared decision-making and patient-centred care." This means discussing disease progression, what is available in the way of financial and practical support (care at home, respite care), future treatments, the adverse effects of treatment for advanced disease, and what could happen at the end of life. Advance care planning should cover Advance Decisions to Refuse Treatment (ADRT) and Do Not Attempt Resuscitation (DNACPR) orders, as well as Lasting Power of Attorney for financial matters and/or health and social care.
